Fresenius Group Overview

Results Center

To archive

Q2/19 Results

Fresenius raises Group sales growth guidance after good second quarter
  • Good organic sales growth across all business segments
  • Growth investments well on track
  • Fresenius Kabi successfully launched first biosimilar in Europe; continued excellent growth in Emerging Markets
  • Fresenius Helios showing strong organic sales growth in Germany and enters successfully Colombian hospital market
  • Fresenius Medical Care’s strategy reinforced by U.S. government’s plans for changes of kidney disease care

Selected Key Figures Q2/19

key figures Q2 19

1 On a comparable basis

2 In constant currency

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA